Cite

HARVARD Citation

    Gleason, A. et al. (2022). Does the FDA‐approved Alzheimer drug aducanumab have a place in the Australian pharmacopoeia?. Medical journal of Australia. 216 (4), pp. 172-174. [Online]. 
  
Back to record